Tinsay Woreta is a Gastroenterology physician. OpenAlex indexes 92 publications with 1,387 citations (h-index 18); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 4th St
Lubbock, TX 794300002
Telephone
806-743-3150Registry record last updated 18 Apr 2016.
Clinical trials
- Nonalcoholic Fatty Liver Disease in HIV Database
Sponsor: Johns Hopkins University
- The Utility of Thromboelastography in Cirrhotic Patients Undergoing Endoscopic Procedures
Sponsor: Johns Hopkins University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year202511 payments
- Madrigal PharmaceuticalsProgram year20258 payments
- Mallinckrodt Hospital Products Inc.Program year20257 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
69.8%Bile Acid23.1%Ursodiol100%Part D≥13 patientsProton pump inhibitor11.8%Pantoprazole Sodium100%Part D<11 patients+ 4 more classes in this area
Cancer & immunology
15.4%Calcineurin inhibitor15.4%Tacrolimus100%Part D<11 patientsCardiovascular
14.8%Calcium channel blocker14.8%Amlodipine Besylate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Body mass index and its association with clinical outcomes in acute liver failure
World Journal of Clinical Cases
2025 - Bariatric surgery and cardiovascular outcomes in patients with obesity, metabolic dysfunction-associated steatotic liver disease, and coronary artery disease: a population-based matched cohort study
European Heart Journal - Quality of Care and Clinical Outcomes
2025
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Charles Rice, MD
The Rockefeller University
Edward Loftus, MD
Mayo Clinic Rochester
Naga Chalasani, MD
Indiana University School of Medicine
Bruce Sands, MD
Icahn School of Medicine at Mount Sinai
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”